Anti-Mouse CD223 (LAG-3) [C9B7W] – Purified (PhenoCyler-Fusion (CODEX)® Ready) - 50 µg

Primary Monoclonal Antibodies>Immune Checkpoints|PhenoCycler®>PhenoCycler® Validated Antibodies|Primary Monoclonal Antibodies>Surfacetag Mouse CD Markers

Next Day 2 - 8°C

LAG-3 is a 70-kD, type-I transmembrane glycoprotein within the Ig superfamily with four extracellular Ig-like domains (D1 to D4) and is structurally homologous to CD4. LAG-3 is a cell surface molecule with various biologic effects on T cell function. It has been reported to be involved in Treg suppressive function. It negatively regulates cellular proliferation, activation, and homeostasis of T cells, in a similar manner to CTLA-4 and PD-1. Human LAG-3 is approximately 70% homologous with murine LAG3, and it binds MHC class II molecules with higher affinity than CD4. As an immune checkpoint receptor, LAG-3 is the target of various drug development programs seeking to expand treatments for cancer and autoimmune disorders. In its soluble form, LAG-3 is being developed as a cancer drug. As an antagonist, LAG-3 antibody can activate T effector cells via the downregulation of the LAG-3 inhibiting signal into pre-activated LAG-3+ cells. In addition, it can inhibit antigen-specific Treg suppressive activity. As an agonist antibody, it can be used to diminish an autoimmune response and is currently being investigated for the treatment of plaque psoriasis.

0.5 mg/ml

CD223 is expressed on T regulatory cells, activated T cells and NK cells.

Monoclonal Antibody, CD223, C9B7W, LAG-3, Mouse, Anti-Mouse CD223 (Lag-3) - Purified, CD223 antigen; CD223; FDC; LAG3; LAG-3; lymphocyte activation gene 3 protein; lymphocyte-activation gene 3; Protein FDC, anti CD223